Amine Marouf

Investment Director VC HealthTech

2024

BNP Paribas Développement invests from pre-seed to pre IPO, in all sectors, >500M€ invested per year, >2Bn€ AUM Nearly 500 portfolio companies 16 in VC HealthTech : Withings, Medincell, Antabio, Sensome, Damae Medical, Treefrog, Implicity, Ciliatech, Brightflow, Poppins, NaoX, Synapse Medecine, Deski, Tissium, Stilla Technologies, Ganymed Robotics

Board member & lead investor

2020

Board member & lead investor

2021

Expert France 2030

2018

Dans le cadre de la doctrine du plan France 2030, l’Etat a décidé depuis 2022 de généraliser la participation d’experts indépendants issus de la société civile à l’évaluation des dossiers déposés auprès d’appels à projets financés par les différents ministères: Au sein d’un jury composé d’autres experts indépendants et d’experts sectoriels Bpifrance, lecture, audition et évaluation de projets afin de statuer ou non sur leur pré-sélection.

Expert

2023

Principal

2017 - 2024

- Market watch, deal opportunities sourcing (800 per year), selection of opportunities. - Relationship management with: research centers, incubators, hospitals, startup studios in Healthcare in Europe. - Investment committees, jury member (iLab, Saclay Spring, SATT, EIT Health), speaker for national innovation programs and events (12 per year), board observer. - Investment: seed stage investments, 2 per year; investing 83M€ in Europe in digital health, medical diagnosis and monitoring, across all therapeutic areas

Expert & Jury member

2018 - 2024

i-Lab, i-Démo, i-Nov etc.

Board observer & co-investor

2020 - 2023

Board observer & co-investor

2020 - 2023

Entrepreneur / Innovation Consultant

2015 - 2017

Clients : start-up, Tech-transfert public offices Fields : Health, Life sciences, R&D Strategic foresight analysis, Start-up launching, Innovation events management